February 7, 2016




  • Do not concomitantly use disinfectants containing quaternary ammonium salts for skin preparation as hyaluronan can precipitate in their presence.
  • Transient increases in inflammation in the injected knee following Monovisc™ injection have been reported in some patients with inflammatory osteoarthritis.



  • Strict aseptic injection technique should be used during the application of Monovisc™.
  • The safety and effectiveness of the use of Monovisc™ in joints other than the knee have not been demonstrated.
  • The effectiveness of Monovisc™ has not been established for more than one course of treatment.
  • STERILE CONTENTS. The pre-filled syringe is intended for single use only. The contents of the syringe should be used immediately after opening. Discard any unused Monovisc™. Do not resterilize.
  • Do not use Monovisc™ if the package has been opened or damaged.
  • Store Monovisc™ in its original package at room temperature (below 77°F/25°C). DO NOT FREEZE.
  • Remove joint effusion, if present, before injecting Monovisc™.
  • Only medical professionals trained in accepted injection techniques for delivering agents into the knee joint should inject Monovisc™ for the indicated use.

Information for Patients

  • Transient pain or swelling may occur after the intra-articular (IA) injection.
  • As with any invasive joint procedure, it is recommended that patients avoid strenuous or prolonged (i.e., more than one hour) weight-bearing activities such as running or tennis within 48 hours following the intra-articular injection.

Use In Specific Populations


The safety and effectiveness of the use of Monovisc™ in pregnant women has not been tested.

Nursing Mothers

It is not known if Monovisc™ is excreted in human milk. The safety and effectiveness of the use of the product in lactating women has not been tested.


The safety and effectiveness of the use of Monovisc™ in pediatric patients ( ≤ 21 years of age) has not been tested.

This monograph has been modified to include the generic and brand name in many instances.

Last reviewed on RxList: 3/21/2014


Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Get the latest treatment options